...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Impact of weight change during the course of concurrent chemoradiation therapy on outcomes in stage IIIB non-small cell lung cancer patients: Retrospective analysis of 425 patients
【24h】

Impact of weight change during the course of concurrent chemoradiation therapy on outcomes in stage IIIB non-small cell lung cancer patients: Retrospective analysis of 425 patients

机译：同时放化疗期间体重变化对IIIB期非小细胞肺癌患者预后的影响：425例患者的回顾性分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: We retrospectively investigated the impact of weight change (WC) during concurrent chemoradiation therapy (C-CRT) on clinical outcomes of stage 3B non-small cell lung cancer (NSCLC) patients. Methods and Materials: A total of 425 patients treated with C-CRT were included. All patients received 60 to 66 Gy of thoracic radiation therapy concurrently with 1 to 3 cycles of platinum-based chemotherapy. Pre- and posttreatment weight measurements on first and last days of C-CRT were used for WC. Patients were divided into 2 groups: group 1 = weight loss (WL); group 2 = weight preservation/gain (WP) for comparative analyses. Results: Following C-CRT, 252 patients (59.3%) experienced WL, while 89 patients (20.9%) and 84 patients (19.8%) showed WP or WG. At median 24.2 months of follow-up, 142 patients (33.4%) were alive (84 WP [48.6%] and 58 WL [23.0%]), and 58 (13.6%) of them were free of disease progression (41 [23.7%] for WP and 17 [6.7%] for WL). Median overall survival (OS), locoregional progression-free survival (LRPFS), progression-free survival (PFS), and distant metastases-free survival (DMFS) for the entire population were 22.8, 14.4, 10.6, and 11.7 months, respectively. Intergroup comparisons between WP and WL cohorts revealed significantly superior OS, LRPFS, PFS, and DMFS in WP patients (P<.05 for each). On multivariate analyses, only WL and advanced T stage were associated with poor prognosis (P<.05). Conclusions: Present results in 425 stage 3B NSCLC patients demonstrated that WL during C-CRT is strongly associated with inferior survival outcomes compared to WP. This emerging finding might be useful by forming an encouraging basis for future investigations in facilitating a way to improve the outcomes of these patients experiencing WL during C-CRT.
机译：目的：我们回顾性研究了同时放化疗（C-CRT）期间体重变化（WC）对3B期非小细胞肺癌（NSCLC）患者临床结局的影响。方法和材料：共纳入425例接受C-CRT治疗的患者。所有患者均接受60至66 Gy的胸腔放疗，并同时进行1至3个周期的铂类化疗。在C-CRT的第一天和最后几天对WC进行治疗前和治疗后的体重测量。患者分为2组：第1组=体重减轻（WL）;第1组=体重减轻（WL）。第2组=体重保持/增重（WP），用于比较分析。结果：C-CRT后，有252名患者（59.3％）经历了WL，而89名患者（20.9％）和84名患者（19.8％）出现WP或WG。在中位24.2个月的随访中，有142例患者（33.4％）存活（84 WP [48.6％]和58 WL [23.0％]），其中58例（13.6％）没有疾病进展（41 [23.7] WP]和WL [17] [6.7％]）。整个人群的中位总生存期（OS），局部无进展生存期（LRPFS），无进展生存期（PFS）和无远处转移生存期（DMFS）分别为22.8、14.4、10.6和11.7个月。 WP和WL队列之间的组间比较显示，WP患者的OS，LRPFS，PFS和DMFS明显更好（每人P <.05）。在多变量分析中，只有WL和晚期T期与不良预后相关（P <.05）。结论：425例3B期NSCLC患者的当前结果表明，与WP相比，C-CRT期间WL与生存期差有关。通过为以后的研究形成令人鼓舞的基础，以便利于改善这些在C-CRT期间经历WL的患者的结局的方式，这一新兴发现可能会有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号